Stepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management Group

Simple item page
dc.contributor.authorÇelik, GE
dc.contributor.authorAydin, Ö
dc.contributor.authorDamadoglu, E
dc.contributor.authorBaççioglu, A
dc.contributor.authorÖzdemir, SK
dc.contributor.authorBavbek, S
dc.contributor.authorEdiger, D
dc.contributor.authorErkekol, FÖ
dc.contributor.authorGemicioglu, B
dc.contributor.authorIsik, SR
dc.contributor.authorKalpaklioglu, AF
dc.contributor.authorKalyoncu, AF
dc.contributor.authorKarakaya, G
dc.contributor.authorKeren, M
dc.contributor.authorMungan, D
dc.contributor.authorOguzülgen, IK
dc.contributor.authorYildiz, F
dc.contributor.authorYilmaz, I
dc.contributor.authorYorgancioglu, A
dc.date.accessioned2024-07-18T12:07:47Z
dc.date.available2024-07-18T12:07:47Z
dc.description.abstractIntroduction of inhaled corticosteroids (ICS) has been the cornerstone of the long-term management of asthma. ICSs either alone or in combination with long-acting beta-2 agonists have been shown to be associated with favorable asthma outcomes. However, asthma con-trol is still reported to be below expectations all around the world. Research in the last decades focusing on the use of ICS/formoterol both as maintenance and as needed (maintenance and reliever therapy approach) showed improved asthma outcomes. As a result of recent developments, Turkish Asthma Guidelines group aimed to revise asthma treatment recommendations. In general, we recommend physi-cians to consider the risk factors for poor asthma outcomes, patients' compliance and expectations and then to determine a personalized treatment plan. Importantly, the use of short-acting beta-2 agonists alone as a symptom reliever in asthma patients not using regular ICS is no longer recommended. In stepwise treatment approach, we primarily recommend to use ICS-based controllers and initiate ICS as soon as possible. We define 2 different treatment tracks in stepwise approaches as maintenance and reliever therapy or fixed-dose therapy and equally recommend each track depending on the patient's risks as well as decision of physicians in a personalized manner. For both tracks, a strong recommendation was made in favor of using add-on treatments before initiating phenotype-specific treatment in step 5. A strong recommendation was also made in favor of using biologic agents and/or aspirin treatment after desensitization in severe asthma when indicated.
dc.identifier.other2979-9139
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/10635
dc.language.isoEnglish
dc.publisherAVES
dc.subjectBUDESONIDE-FORMOTEROL
dc.subjectDOUBLE-BLIND
dc.subjectINHALED CORTICOSTEROIDS
dc.subjectEARLY INTERVENTION
dc.subjectTHERAPY
dc.subjectMAINTENANCE
dc.subjectEFFICACY
dc.subjectRISK
dc.subjectEXACERBATION
dc.subjectMETAANALYSIS
dc.titleStepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management Group
dc.typeReview

Files

Collections

Web of Science Koleksiyonu